Loss of RUBCN/rubicon in adipocytes mediates the upregulation of autophagy to promote the fasting response

Autophagy. 2022 Nov;18(11):2686-2696. doi: 10.1080/15548627.2022.2047341. Epub 2022 Mar 14.

Abstract

Upon fasting, adipocytes release their lipids that accumulate in the liver, thus promoting hepatic steatosis and ketone body production. However, the mechanisms underlying this process are not fully understood. In this study, we found that fasting caused a substantial decrease in the adipose levels of RUBCN/rubicon, a negative regulator of macroautophagy/autophagy, along with an increase in autophagy. Adipose-specific rubcn-knockout mice exhibited systemic fat loss that was not accelerated by fasting. Genetic inhibition of autophagy in adipocytes in fasted mice led to a reduction in fat loss, hepatic steatosis, and ketonemia. In terms of mechanism, autophagy decreased the levels of its substrates NCOA1/SRC-1 and NCOA2/TIF2, which are also coactivators of PPARG/PPARγ, leading to a fasting-induced reduction in the mRNA levels of adipogenic genes in adipocytes. Furthermore, RUBCN in adipocytes was degraded through the autophagy pathway, suggesting that autophagic degradation of RUBCN serves as a feedforward system for autophagy induction during fasting. Collectively, we propose that loss of adipose RUBCN promotes a metabolic response to fasting via increasing autophagic activity.

Keywords: Adipocytes; NCOA1; NCOA2; RUBCN; autophagy; fasting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / metabolism
  • Adipogenesis
  • Animals
  • Autophagy* / genetics
  • Carrier Proteins / metabolism
  • Fasting
  • Fatty Liver* / metabolism
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Mice
  • Mice, Knockout
  • PPAR gamma / genetics
  • Up-Regulation / genetics

Substances

  • Carrier Proteins
  • PPAR gamma
  • Intracellular Signaling Peptides and Proteins

Grants and funding

T.Ya. was supported by the Takeda Science Foundation. SN was supported by AMED-PRIME (20gm6110003h0004), MEXT/JSPS KAKENHI (21H05145, 21H02428, and 19K22429), the Senri Life Science Foundation, the Takeda Science Foundation, the Nakajima Foundation, the MSD Life Science Foundation, the Astellas Foundation for Research on Metabolic Disorders, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Mitsubishi Foundation, and the Uehara Memorial Foundation. T.Yo. was supported by JST CREST (Grant Number JPMJCR17H6), AMED (Grant Number JP21gm5010001), the Takeda Science Foundation, the JSPS A3 Foresight Program, and the HFSP research grant.